Ernexa Therapeutics director David Polinsky files initial beneficial ownership statement
ERNA•Initial Form 3 filing
Director David Polinsky reported 8,000 Ernexa Therapeutics common shares held indirectly through Polo3K, LLC in an initial Form 3 filing.
